Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte By Investing.com
Update: 2025-11-04
Description
**Summary:**Prelude Therapeutics secures a significant deal with Incyte, receiving $60 million upfront for its experimental JAK two inhibitor targeting rare blood cancers. The agreement could potentially yield up to $882 million more if certain milestones are met. Prelude also announces a shift in focus to advance another drug program, a KAT six A degrader for ER positive breast cancer, while pausing work on its SMARCA two degrader. The deal extends Prelude's cash reserves, with potential for further growth if Incyte fully commits to the JAK two program.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
